Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07184853
What this trial is testing

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Who this might be right for
Graft vs Host Disease
First Affiliated Hospital of Zhejiang University 122
Testing effectiveness (Phase 2)UnknownNCT03558607
What this trial is testing

The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Who this might be right for
Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
Seoul National University Hospital 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT04817007
What this trial is testing

Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 216
Large-scale testing (Phase 3)Study completedNCT01969838
What this trial is testing

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 432
Early research (Phase 1)Ended earlyNCT01751425
What this trial is testing

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Who this might be right for
Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 Positive in RemissionMinimal Residual Disease+1 more
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Ended earlyNCT00726232
What this trial is testing

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Who this might be right for
Myeloproliferative Neoplasm (MPN)
Incyte Corporation 73
Large-scale testing (Phase 3)Study completedNCT04052425
What this trial is testing

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Who this might be right for
Non-segmental Vitiligo
Incyte Corporation 330
Testing effectiveness (Phase 2)Study completedNCT02267278
What this trial is testing

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Who this might be right for
Myeloproliferative Diseases
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT05870475
What this trial is testing

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Who this might be right for
Polycythemia Vera
Institute of Hematology & Blood Diseases Hospital, China 94
Not applicableUnknownNCT05762874
What this trial is testing

Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Myelofibrosis
Assiut University 51
Testing effectiveness (Phase 2)Study completedNCT04348695
What this trial is testing

Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.

Who this might be right for
Coronavirus Infection
Fundación de investigación HM 94
Early research (Phase 1)Study completedNCT02493530
What this trial is testing

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Who this might be right for
MyelofibrosisPolycythemia Vera
Vanderbilt-Ingram Cancer Center 60
Not applicableUnknownNCT03959371
What this trial is testing

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

Who this might be right for
Myelofibrosis
Margherita Maffioli 620
Large-scale testing (Phase 3)Study completedNCT01243944
What this trial is testing

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Who this might be right for
Polycythemia Vera
Incyte Corporation 222
Testing effectiveness (Phase 2)Active Not RecruitingNCT06909136
What this trial is testing

Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly
Suzhou Junjing BioSciences Co., Ltd. 33
Early research (Phase 1)Study completedNCT01164163
What this trial is testing

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes+2 more
Children's Oncology Group 49
Early research (Phase 1)Study completedNCT03012230
What this trial is testing

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Who this might be right for
Metastatic Malignant Neoplasm in the BoneStage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma
Mayo Clinic 12
Not applicableApproved For MarketingNCT03147742
What this trial is testing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Who this might be right for
Graft-versus-host Disease (GVHD)
Incyte Corporation
Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Testing effectiveness (Phase 2)Looking for participantsNCT07356245
What this trial is testing

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Who this might be right for
T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell+5 more
Jonathan Brammer 44
Next Page